DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline ...

MINNEAPOLIS-- (BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction ...

Key Laboratory of Agricultural Biosafety and Green Production of Upper Yangtze River (Ministry of Education), College of Horticulture and Landscape Architecture, Southwest University, Chongqing, China ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth ...

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced ...

This study presents important findings on the insecticidal mechanism of betulin, a plant-derived metabolite, in controlling the aphid Myzus persicae and it provides a demonstration that betulin ...

B7-33 is not believed to mediate an nitric oxide (NO)-dependent pathway, but instead, it is thought to participate in endothelial-dependent relaxation, intermediating calcium- and potassium ...